摘要
目的:探讨miR-30c在骨肉瘤组织中的表达及其临床意义。方法:37例骨肉瘤组织标本均来自于2007年1月至2015年1月间在新疆医科大学第六附属医院住院接受治疗的骨肉瘤患者,实时定量PCR和原位杂交分析骨肉瘤组织中miR-30c表达情况。单因素和多因素分析miR-30c表达与骨肉瘤临床病理参数和预后之间的相关性。结果:实时定量PCR检测和原位杂交检测分析结果一致表明:骨肉瘤组织中miR-30c的表达水平显著低于正常骨组织,差异有统计学意义(P<0.05);miR-30c低表达组肿瘤与更晚分期和中低分化程度、肿瘤复发有相关性(P<0.05);多元回归分析表明,miR-30c低表达与骨肉瘤患者生存期更短有关(P<0.01);miR-30c低水平表达是骨肉瘤患者预后的一个独立危险因数。结论:miR-30c表达下调能够促进肿瘤进展,是预测骨肉瘤患者预后的可靠指标,miR-30c也具有成为骨肉瘤靶向治疗靶点的潜力。
Objective:To investigate the expression and clinical significance of miR-30 c in osteosarcoma.Methods:37 osteosarcoma specimens were collected from osteosarcoma patients hospitalized in the Sixth Affiliated Hospital of Xinjiang Medical University from January 2007 to January 2015.Real-time quantitative PCR and in situ hybridization were used to analyze the expression of miR-30 c in osteosarcoma.The correlation between the expression of miR-30 c and the clinicopathological parameters and prognosis of osteosarcoma were analysed by Univariate and multivariate analysis.Results:The results of Real-time PCR and in situ hybridization showed that the expression of microRNA-30 c in osteosarcoma tissue was significantly lower than that in normal bone tissue,and the difference was statistically significant(P<0.05).Tumors with low expression of miR-30 c were correlated with later stage,moderately and poorly differentiated and recurrence(P<0.05).Multivariate regression analysis showed that the low expression of miR-30 c was associated with shorter survival time in osteosarcoma patients(P<0.01).Low level expression of miR-30 c was an independent risk factor for prognosis in patients with osteosarcoma.Conclusion:The down-regulation of the expression of miR-30 c can promote the progression of osteosarcoma and is a reliable prognostic indicator for osteosarcoma patients.miR-30 c may also be a potential target for targeted therapy of osteosarcoma.
作者
孙荣鑫
舒莉
巨啸晨
柴浩
杨德勇
Sun Rongxin;Shu Li;Ju Xiaochen;Chai Hao;Yang Deyong(Department of Joint Surgery,Sixth Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830002,China)
出处
《现代肿瘤医学》
CAS
2019年第12期2150-2153,共4页
Journal of Modern Oncology
基金
新疆维吾尔自治区自然科学基金项目(编号:2017D01C257)
作者简介
孙荣鑫(1977-),男,新疆人,副主任医师,博士研究生,主要从事关节外科临床工作。E-mail:sweetwords2001@163.com.
